> ## Content Index > Fetch the complete content index at: https://www.bullished.co/llms.txt > Use this file to discover other available public pages before exploring further. # Nautilus Third-Quarter Loss Widens To $15.6 Million With $114.3 Million In Cash And Investments - URL: https://www.bullished.co/nautilus-third-quarter-loss-widens-to-15-6-million-with-114-3-million-in-cash-and-2d2b2c73/ - Published: 2026-10-27T10:23:55.000Z - Updated: 2026-10-31T00:25:24.000Z - Description: The pre-product proteomics company's operating costs rose 10%, and it still points to mid-2027 for instrument availability. - Author: Matteo Parrino - Tags: Earnings, NAUT, Industry: Healthcare [Nautilus Biotechnology](https://www.bullished.co/tag/naut/), which is building a platform to measure proteins, said its third-quarter [net loss widened to $15.6 million](https://www.sec.gov/Archives/edgar/data/0001808805/000180880526000049/exhibit991-q3268xkearnings.htm?ref=bullished.co) from $13.6 million a year earlier, as operating expenses rose 10%. The company still points to instrument availability in the middle of 2027. ## Costs up, interest income down The loss came to $0.12 per share, against $0.11 a year earlier. Operating expenses were $16.9 million, up $1.5 million from $15.5 million, which the company attributed to higher laboratory and professional services costs and higher salaries and benefits, partly offset by lower facilities expenses. Revenue was $0.2 million, mostly grant revenue tied to a Michael J. Fox Foundation grant plus service revenue from its Iterative Mapping Early Access Program. Interest income fell to $1.2 million from $1.9 million a year earlier. For the first nine months, the net loss was $44.8 million, compared with $45.2 million a year earlier. ## A pre-product proteomics developer Nautilus is a development-stage life sciences company working on a platform to measure proteins, using instruments, consumables and software to analyze single protein molecules through a method it calls Iterative Mapping. Its Voyager platform is not yet commercially available. The quarter's progress included a peer-reviewed Nature Methods paper on Iterative Mapping and first development data on oncology assays, including AKT1, shown at World HUPO 2026\. The company said that data matched the performance profile of its Tau assay, and it is advancing toward twenty proteoform assays planned through mid-2028. CEO Sujal Patel said the proteoform expansion initiative is "on-track" and that the progress reinforces the company's confidence in "our planned instrument availability in the middle of 2027." ## Cash and a $6 million consortium award Cash, cash equivalents and investments totaled $114.3 million at September 30\. Total stockholders' equity was $116.6 million, down from $157.0 million at the end of 2025, and net cash used in operations for the nine months was $40.1 million. After quarter end, Nautilus joined SEEDS, a four-year research consortium funded by ARPA-H. ARPA-H has awarded the group [$51.7 million](https://www.globenewswire.com/news-release/2026/10/27/3388769/0/en/nautilus-to-measure-proteoforms-driving-alzheimer-s-disease-and-cancer-in-arpa-h-funded-seeds-consortium.html?ref=bullished.co), and Nautilus expects up to $6 million to deploy Voyager on proteoforms tied to Alzheimer's disease and cancer. The company cautioned that the SEEDS funding could be reduced, delayed or terminated. Nautilus held a webcast on the results at 8:30 a.m. ET Tuesday, and its quarterly report on Form 10-Q is still to be filed. Learn - [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations) From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples ### Sources - [8-K Filing — Nautilus Biotechnology, Inc. (NAUT)](https://www.sec.gov/Archives/edgar/data/0001808805/000180880526000049/naut-20261027.htm?ref=bullished.co) — SEC EDGAR - [Exhibit exhibit991-q3268xkearnings.htm — Nautilus Biotechnology, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001808805/000180880526000049/exhibit991-q3268xkearnings.htm?ref=bullished.co) — SEC EDGAR - [Nautilus Biotechnology Reports Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/10/27/3388771/0/en/nautilus-biotechnology-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com - [Nautilus to Measure Proteoforms Driving Alzheimer’s Disease](https://www.globenewswire.com/news-release/2026/10/27/3388769/0/en/nautilus-to-measure-proteoforms-driving-alzheimer-s-disease-and-cancer-in-arpa-h-funded-seeds-consortium.html?ref=bullished.co) — globenewswire.com ### More on Nautilus Biotechnology - [Nautilus Eyes A Capital Raise By Mid-2027 As CEO Pitches Proteoforms, Not Gene Count, As The Key To Biology](https://www.bullished.co/nautilus-eyes-a-capital-raise-by-mid-2027-as-ceo-pitches-proteoforms-not-gene-count-as-the-281d71fe/) - [Nautilus Eyes A Fundraise Before Mid-2027, Though Cash Lasts Into 2028](https://www.bullished.co/nautilus-eyes-a-fundraise-before-mid-2027-though-cash-lasts-into-2028-b929f5d2/) - [Nautilus Biotechnology Lines Up A $125 Million Stock-Sale Program With $114.3 Million In Cash Left](https://www.bullished.co/nautilus-biotechnology-lines-up-a-125-million-stock-sale-program-with-114-3-million-in-3e6bebd4/) [All Nautilus Biotechnology (NAUT) coverage →](https://www.bullished.co/tag/naut/)